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The Epstein-Barr virus (EBV) BZLF1 (Z) immediate-early transactivator initiates the switch between latent
and productive infection in B cells. The Z protein, which has homology to the basic leucine zipper protein c-Fos,
transactivates the promoters of several replicative cycle proteins. Transactivation efficiency of the EBV BMRF1
promoter by Z is cell type dependent. In B cells, in which EBV typically exists in a latent form, Z activates the
BMRF1 promoter inefficiently. We have discovered that the p65 component of the cellular factor NF-KB
inhibits transactivation of several EBV promoters by Z. Furthermore, the inhibitor of NF-KB, IKBBa, can
augment Z-induced transactivation in the B-cell line Raji. Using glutathione S-transferase fusion proteins and
coimmunoprecipitation studies, we demonstrate a direct interaction between Z and p65. This physical
interaction, which requires the dimerization domain of Z and the Rel homology domain of p65, can be
demonstrated both in vitro and in vivo. Inhibition of Z transactivation function by NF-KB p65, or possibly by
other Rel family proteins, may contribute to the inefficiency of Z transactivator function in B cells and may be
a mechanism of maintaining B-cell-specific viral latency.
Epstein-Barr virus (EBV) is a human herpesvirus which
infects primarily B cells and epithelial cells (reviewed in
reference 33). Infection with EBV is strongly associated with
the development of Burkitt's lymphoma in B cells and naso-
pharyngeal carcinoma (45) in epithelial cells. Infection of
normal B cells with EBV results in the establishment of a
latent state, with entry into the viral replicative cycle typically
occurring in only a very small number of these cells (33, 45). In
contrast, infection of epithelial cells with EBV results in viral
production and shedding into the saliva (66). The BZLF1 (Z)
protein is the first productive cycle protein that is expressed
during reactivation of viral replication in B cells (14, 15, 70).
The immediate-early Z protein disrupts viral latency through
transactivation of early EBV genes which contain upstream
Z-binding sites (9, 11, 13, 14, 16, 30, 31, 42, 43, 64, 71). Z also
can activate its own expression (19, 71). Although the Z
protein lacks the classic heptad leucine repeats, Z belongs to
the basic leucine zipper (bZIP) family of proteins, containing a
basic DNA-binding domain adjacent to a coiled-coil dimeriza-
tion domain (18). Z protein structure bears resemblance to the
structure of the c-Fos leucine zipper protein (18); however,
unlike c-Fos, Z has not been shown to heterodimerize with any
other bZIP protein.
We have shown that some EBV early promoters, such as the
BMRF1 (early antigen-diffuse) promoter, are transactivated
very poorly by Z in certain lymphoid cell lines, while in
epithelial cell lines, the same promoters are highly Z respon-
sive (29, 53). In lymphoid cell lines not supporting efficient Z
function, there may exist inhibitors of Z transactivation. One
candidate for such a B-cell-specific inhibitor of Z is the cellular
factor NF-KB.
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As with Z, constitutive NF-KB function is cell type specific
(39, 63). Although NF-KB is expressed in many types of cells,
in most instances NF-KB is complexed with IKB and held in an
inactive state within the cytoplasm (3). In mature B cells, in
which NF-KB function regulates the expression of the immu-
noglobulin kappa protein (39, 63), a portion of NF-KB is
dissociated from IKB and thus found in the nucleus in an active
form (3).
Classic NF-KB is composed of two proteins, p50 and p65 (4).
The p50-p65 complex can bind to NF-KB sites within certain
promoters (63) and activate transcription. These two proteins
have been found to have structural similarity to the protein
product of the c-rel proto-oncogene and other Rel-like pro-
teins (21, 34, 52, 57). The p50 protein is processed from a
larger precursor protein, p105, which contains a series of
domains called ankyrin repeats (21, 34), and is also closely
related to another ankyrin-containing Rel type protein called
plO0/p52 (50). The MAD-3 form of IKB (IKBoL) contains
ankyrin repeats without the Rel homology domain (27). A
second group of Rel-like proteins, including p65 (52, 57), c-Rel
(73), RelB (59), and the Drosophila protein Dorsal (69), all
have Rel domains without ankyrin repeats. A newly discovered
alternatively spliced form of p65, termed p65A, lacks 10 amino
acids within the Rel domain of p65 (58). Overexpression of this
naturally occurring variant of p65 in Rat-1 cells produces
transformed foci which are tumorigenic in nude mice (48). The
complex patterns of heterodimerization between the Rel fam-
ily members are now being elucidated (reviewed in reference
51). In addition to multimerization between Rel family pro-
teins, interfamily interactions involving Rel proteins exist.
Recently, it was found that the p50 and p65 proteins can
physically interact with the bZIP protein, NF-IL6 (38, 67).
Here we report the physical and functional interaction
between a member of the bZIP family of transactivators, Z,
and the Rel protein, NF-KB p65. We show that p65 functions
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as an inhibitor of Z-induced transactivation of early EBV
promoters and that Z and p65 can physically interact with one
another both in vitro and in vivo. This ability of p65 to inhibit
the function of the EBV protein which triggers disruption of
viral latency may partly explain the tendency of EBV infection
to remain latent in B cells.
MATERIALS AND METHODS
Plasmid constructions. The pEA-BS-CAT construct, which
contains the EBV BMRF1 promoter sequences from -331 to
+ I linked to the chloramphenicol acetyltransferase (CAT)
reporter, has been described elsewhere (32). The pBHRF1-
CAT plasmid contains a 1,020-bp NaeI-to-HincII fragment of
the EBV BHRF1 promoter (26) (EBV positions 52800 to
53819) linked to CAT in the plasmid vector pBS+ (Strat-
agene). The pHD1013 expression plasmid contains a 2.1-kb
PstI fragment of the cytomegalovirus (CMV) immediate-early
promoter/enhancer in the PstI site of pGEM2 (Promega) (30).
Plasmid CMV-Z contains the Z cDNA from plasmid
pKSVZ41 (a gift from Alain Sergeant) (22) downstream and
under the control of the CMV immediate-early promoter in
pHD1013. Construction of the CMV promoter control vector,
pCMV4T, has been described elsewhere (72). Plasmids
pCMV4T-p65, pCMV4T-p65A, and pCMV4T-IKB contain
cDNAs encoding human NF-KB p65 (57), p65A (58), and
IKBoL/MAD-3 (27) inserted into the pCMV4T expression
vector (67). Plasmid pGST-Z was created by inserting the
cDNA encoding full-length Z (a gift of Paul Farrell) blunt end
and in frame into the SmaI site of pGEX-3X (Pharmacia).
Glutathione S-transferase (GST) ZA1-79, GST ZA1-133, and
GST ZA200-227 contain Z cDNA lacking coding sequence for
the amino acid residues indicated by the numbers used to
name each plasmid (22, 32) (gifts of Alain Sergeant and Frank
Furnari) inserted into pGEX-2T (Pharmacia). The GST-p65
construct contains the intact p65 coding sequences down-
stream of the GST protein (67) in plasmid pGEX-lN (AM-
RAD Corp.). The Z-containing EcoRI fragment from
pKSVZ41 was inserted into a modified pFlag (International
Biotechnologies, Inc.) vector (8) to produce pFlag Z. Similarly,
a fragment encoding the first 171 amino acids of a Z cDNA was
generated by PCR and inserted into the modified pFlag vector,
creating pFlag ZACOOH. The plasmid for in vitro expression
of the wild-type Z protein (a gift of Paul Farrell) and the point
mutants of the Z dimerization domain (a gift of Erik Fleming-
ton and Samuel Speck) have been described in detail else-
where (20, 56). Plasmids for in vitro expression of wild-type
p65, p65A, and p65 with a four-amino-acid substitution from
KRKR to DQNQ in the nuclear localization signal of p65 (p65
ANLS; a gift of Amer Beg) have been described elsewhere (6,
67). The in vitro-translated proteins p65 A313, p65 A285, and
p65 A196 were created by runoff transcription ending at BspHI,
EcoRI, and BglII sites, respectively, within the wild-type p65
reading frame.
DNA preparation and transfections. Plasmid DNA was
purified through two sequential cesium chloride gradients.
Electroporation of both lymphoid and epithelial cells was
performed as previously described (31, 70). Approximately 5
x 106 cells were used for each condition.
Cell lines. P3HR1 and Raji are EBV-positive Burkitt's
lymphoma B-cell lines which were maintained in RPMI 1640
medium supplemented with 10% fetal calf serum. The cervical
carcinoma cell line HeLa was grown in Dulbecco modified
Eagle medium H with 5% fetal calf serum.
CAT assays. Cells were harvested 48 h after transfection
with plasmid DNA. Cell extracts were incubated at 37°C with
"4C-labeled chloramphenicol in the presence of acetyl coen-
zyme A as previously described (24). The percent acetylation
of chloramphenicol was quantitated by thin-layer chromatog-
raphy, followed by autoradiography and either scintillation or
Phosphorlmager (Molecular Dynamics) counting. The CAT
assays were repeated with less extract if results were not in the
linear range (less than 70% acetylated).
Synthesis and radiolabeling of proteins. Plasmids encoding
the GST fusion proteins were introduced into Escherichia coli
HB101. An overnight culture was diluted 1:10 in Luria-Bertani
broth with ampicillin, grown for 2 h, and then induced with 0.4
mM isopropyl-3-thiogalactopyranoside (IPTG) for 2 h at 37°C.
Bacteria were pelleted and resuspended in 1/10 volume of
phosphate-buffered saline (PBS), sonicated, and centrifuged in
Eppendorf tubes at 13,000 rpm. These supernatants were
either used directly for immunoprecipitation or incubated with
glutathione (GSH)-agarose beads (Sigma). Swollen GSH-aga-
rose beads were reacted for 20 min at room temperature with
extracts containing the GST proteins at a ratio of 50 ,u of
beads per ml of extract. The coated beads were then washed
three times in Z/p65 buffer (20 mM N-2-hydroxyethylpipera-
zine-N'-2-ethanesulfonic acid [HEPES; pH 7.7], 25 mM NaCl,
2.5 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol [DTT],
0.05% Nonidet P-40) and then used in GST precipitation
experiments.
The Flag Z and Flag ZACOOH plasmids were introduced
into E. coli DH5otF' (Gibco BRL), grown to log phase, and
induced for 4 h with IPTG. Proteins were harvested first by
incubation in 50 mM Tris-HCl (pH 8)-i mM EDTA-100 mM
NaCl-0.1 mM phenylmethylsulfonyl fluoride-1 mM sodium
metabisulfite-1 mg of lysozyme per ml. Sodium deoxycholate
was added to 16 mg/ml, and the lysates were incubated at 37°C
for 10 min and then sonicated. The cellular debris was pelleted
at 12,000 x g, and the supernatant was dialyzed against 25 mM
HEPES-12.5 mM MgCl2-100 mM KCl-30 ,uM phenylmethyl-
sulfonyl fluoride-12.5 FLM sodium metabisulfite-1 mM DTT-
20% glycerol and then used directly for 32p labeling. The Flag
protein labeling reaction mixture contained 20 mM Tris-HCl
(pH 7.5), 1 mM DTT, 10 mM NaCl, 12 mM MgCl2, 2 Rl of
[-y-32P]ATP (Amersham Life Sciences; catalog no. PB.10168),
10 U of heart muscle kinase (Sigma; catalog no. P-2645), and
2 RI of crude bacterial extract containing Flag Z protein in a
total volume of 30 [L (8). Proteins were labeled at 37°C for 1
h. In vitro transcription and translation for 35S labeling reac-
tions were performed as suggested by the manufacturer (Pro-
mega).
GST precipitations. Ten microliters of GST, GST-Z, or
GST-p65-coated GSH-agarose beads was incubated with ei-
ther 10,000 cpm of 32P-labeled Flag protein or 10 RI of
reticulocyte lysate containing 35S-labeled Z or p65 protein in a
1-ml total volume of Z/p65 buffer. Following a 1-h room
temperature incubation, the beads were washed five times with
Z/p65 buffer and boiled in sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) loading buffer.
The proteins were then separated on a 10% denaturing
polyacrylamide gel and submitted to autoradiography (en-
hanced with 1 M sodium salicylate for 35S-labeled proteins).
To demonstrate a genuine DNA-independent interaction
between Z and p65, the crude bacterial extracts containing
GST fusion proteins and the reticulocyte lysates containing
35S-labeled proteins were treated with DEAE-Sephacel prior
to GST precipitation as previously described (1). As a marker
for the removal of nonspecific DNA, protein extracts were
spiked with a 32P-labeled tracer probe containing the class I
major histocompatibility complex NF-KB DNA-binding site (5)
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FIG. 1. Z-induced transactivation of several EBV promoters is inhibited by NF-KB p65. (A) Plasmid pBHRF1-CAT (3 jig) was transfected into
the HeLa epithelial cell line with various combinations of expression plasmids (each at 3 ,ug) as follows (left to right): pBHRFI-CAT with the
vectors pCMV4T and pHD1013; pBHRFI-CAT with pCMV4T and the Z expression vector CMV-Z; pBHRF1-CAT with the p65 expression
vector pCMV-p65; pBHRF1-CAT with the p65A expression vector pCMV4T-p65A; pBHRF1-CAT with pCMV-p65 and CMV-Z; and
pBHRF1-CAT with pCMV4T-p65zA and CMV-Z. The p65 vector decreased Z transactivation of the BHRF1 promoter. Coexpression of p65A with
Z inhibited Z transactivation of the BHRF1 promoter only to a moderate degree in comparison with the inhibition of Z by p65. (B) The
BMRF1-CAT (pEA-BS-CAT) plasmid (5 ,ug) was transfected into the HeLa epithelial cell line with various combinations of expression plasmids
(each at 3 jug) as follows (left to right): BMRF1-CAT with the vectors pCMV4T and pHD1013; BMRFI-CAT with pCMV-p65; BMRF1-CAT with
the IKB expression vector pCMV4T-IKB; BMRF1-CAT with CMV-Z; BMRF1-CAT with pCMV-p65 and CMV-Z; BMRF1-CAT with pCMV-p65
and pCMV4T-IKB; and BMRF1-CAT with pCMV-p65, CMV-Z, and pCMV4T-IKB. As with the BHRF1 promoter, the p65 vector decreased Z
transactivation of the BMRF1 promoter (fifth column). The addition of the IKB expression vector overcame the inhibitory effect of p65 upon
Z-induced transactivation of the BMRF1 promoter (seventh column) (C) The BHRF1-CAT plasmid (3 ,ug) was transfected into the Raji B-cell
line with various combinations of expression plasmids (each at 3 ,ug) as follows (left to right): the vectors pCMV4T and pHD1013; pCMV4T-IKB;
pCMV4T and CMV-Z; and pCMV4T-IKB and CMV-Z. Coexpression of IKB with Z increased Z-induced transactivation of BHRF1-CAT fourfold
above the level of transactivation due to Z alone in Raji cells. Error bars indicate the standard error of the mean.
and then equally divided for GST precipitation studies with
extracts untreated or treated with DEAE-Sephacel.
Immunoprecipitations and immunoblotting. Approximately
107 HeLa cells per condition were transfected by electropora-
tion with various combinations of Z and p65 expression vectors
or the appropriate negative control vectors. At 24 h posttrans-
fection, the cells were scraped from the dishes, washed twice
with ice-cold PBS, resuspended in 250 [L1 of Z/p65 buffer, and
sonicated. The cellular debris was removed by centrifugation,
and 100 of supernatant was reacted with either 15 p.l of
normal rabbit serum or 15 p.l of anti-p65 serum (Santa Cruz
Biotechnology; catalog no. SC-109) in a total volume of 500 p.l
of Z/p65 buffer. The reactions were rocked for 1 h at 4°C
before 20 of preswollen protein A-Sepharose beads (Phar-
macia) was added. Samples were again rocked for 1 h at 4°C,
washed three times with Z/p65 buffer, and boiled in SDS-
PAGE loading buffer. The proteins were then separated on a
10% denaturing polyacrylamide gel and transferred to nitro-
cellulose (Schleicher & Schuell). Ten microliters of each
original cellular extract (directly loaded to demonstrate pro-
tein levels prior to immunoprecipitation) were also separated
on the denaturing gel and transferred.
Approximately 5 x 105 P3HR1 cells were equally divided
and either induced with 5 mM sodium butyrate plus 30 ng of
12-O-tetradecanoylphorbol-13-acetate (TPA) per ml or left
uninduced. After 34 h, the cells were pelleted, washed twice
with ice-cold PBS, resuspended in 500 p.l of Z/p65 buffer, and
sonicated. The cellular debris was removed by centrifugation,
and supernatant containing 1.9 mg of cellular protein was
reacted with either normal rabbit serum (3 p.g of protein) or
anti-p65 serum (3 p.g) (Santa Cruz Biotechnology) in a total
volume of 500 pL. of Z/p65 buffer. Hereafter, the immunopre-
cipitation was performed exactly as for the HeLa cell experi-
ment.
Immunoblotting was performed in PBS with 3% powdered
milk with a 1:10 dilution of monoclonal antibody BZ.1 (a gift
of Alan Rickinson) (74) and a 1:2,000 dilution of goat anti-
mouse kappa-chain horseradish peroxidase-conjugated serum
(Southern Biotechnology Associates, Inc.; catalog no. 1050-
05), followed by enhanced chemiluminescence performed as
recommended by the manufacturer (Amersham Life Scienc-
es). Rabbit anti-p65 serum was used at 1:2,000 in 3% milk-
PBS, and the secondary antibody was donkey anti-rabbit
horseradish peroxidase-conjugated serum (Amersham Life
Sciences) at 1:3,000, in the procedure described above for
anti-Z immunoblotting.
RESULTS
The p65 component of NF-KB inhibits the ability of Z to
activate EBV early promoters in HeLa cells. In search of a
mechanism for the cell type specificity of Z transactivation
function, we first studied the ability of p65 to interfere with
Z-induced transactivation of the BHRF1 early promoter of
EBV (42). In HeLa cells, the IKB proteins physically bind to
the p65 component of NF-KB, thereby rendering NF-KB
inactive (3). We introduced an expression vector for p65 into
HeLa cells to test the ability of transiently overexpressed p65
to inhibit transactivation of the BHRF1 promoter by Z. In the
HeLa epithelial cell line, Z by itself efficiently activated the
BHRF1 promoter (Fig. 1A). Although p65 alone had little
effect on BHRF1 activity, coexpression of p65 with Z totally
inhibited transactivation of BHRF1 by Z. Western blotting
(immunoblotting) confirmed that this functional inhibition of
Z is not caused by decreased expression of Z through inhibi-
tion of the CMV promoter driving Z expression in the
presence of p65 (see Fig. 8A).
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p65A, lacks amino acids 222 to 231 of p65 (58). The deletion
within the Rel domain of this variant p65 protein is known to
interfere with multimerization such that the p65A protein is
unable to homodimerize or heterodimerize with NF-KB p50
and only weakly interacts with p65 (58). We examined the
effect of this multimerization-defective form of p65 on Z. As
shown in Fig. 1A, p65A had a less profound effect upon the
Z-induced transactivation of BHRF1-CAT, suggesting that
amino acid residues 222 to 231 (within the Rel homology
domain) of p65 are necessary for efficient inhibition of Z by
p65.
We next tested whether transactivation of a second EBV
early promoter, BMRF1, by Z might also be inhibited by p65.
Our previous studies have demonstrated that the BMRF1
promoter, which controls the expression of the early antigen-
diffuse polymerase cofactor (40), responds to Z in a cell-type-
specific manner (29, 32). In the lymphoid cell lines Jurkat and
Louckes, Z has very little effect on the BMRF1 promoter;
however, in the epithelial cell line HeLa, Z can efficiently
activate BMRF1. Expression of the Z protein alone produced
the expected transactivation of the BMRF1 promoter linked to
CAT (Fig. 1B). When a p65 expression vector was introduced
along with the Z expression vector, activation of BMRF1 by Z
was inhibited by 88%. Overexpression of IKBot with Z and p65
resulted in reversal of the p65-induced inhibition of Z. Addi-
tionally, gel retardation studies indicate that while Z alone can
bind to the BMRF1 promoter (32), p65 alone does not (29a),
making it unlikely that p65 is merely competing with Z for
DNA binding sites within this promoter.
Endogenous NF-KB p65 expression inhibits Z function in
the B-cell line Raji. In B cells, IKB does not efficiently
sequester NF-KB into the cytoplasm, leaving a portion of
NF-KB free to remain nuclear in localization and functional
(39, 63). We tested whether overexpression of IKB in the B-cell
line Raji might inactivate p65, allowing Z to function more
efficiently. Like other mature B cells, Raji cells are known to
contain constitutive NF-KB-binding activity in the nucleus (23).
Although expression of Z alone resulted in some transactiva-
tion of BHRF1 in Raji cells (Fig. 1C), overexpression of IKBUx
increased the ability of Z to transactivate the BHRF1 pro-
moter fourfold (Fig. IC, last column). The positive effect of
IKB in Raji cells is presumably due to overexpression of IKBQx
and the sequestration of endogenous p65 into the cytoplasm,
thereby eliminating p65-induced inhibition of Z function in the
nucleus. However, a more indirect effect of IKBco upon Z
cannot be ruled out.
Z and p65 physically associate with one another. One
possible means by which p65 inhibits Z is through a direct
contact between the proteins. To test whether such an inter-
action takes place, we performed precipitation experiments
using a GST-p65 fusion protein. Full-length Z protein labeled
to very high specific activity with 32P (Fig. 2A) was not
precipitated by GSH-agarose beads alone or by beads coated
with GST protein (Fig. 2B). However, labeled Z protein was
efficiently precipitated by using GST-p65 linked to GSH-
agarose beads (Fig. 2B).
To begin to determine which portion of Z is necessary for
the contact with the p65 protein, a truncated form of Z (Flag
ZACOOH) in which the carboxy-terminal 74 amino acids of Z
had been deleted was 32p labeled and compared with full-
length Z for the ability to bind to GST-p65 (Fig. 2C). In
contrast to the full-length Z protein, the carboxy-terminal
truncated form of Z was unable to associate with p65. These
last 74 amino acids of Z contain the basic DNA-binding
domain and the coiled-coil dimerization domain.
Because Z and p65 are both DNA-binding proteins, the
possibility exists that they each nonspecifically interact with
contaminating DNA present in bacterial or reticulocyte lysates.
This genomic DNA could then serve as a bridge between two
DNA-binding proteins, creating the appearance of a protein-
protein interaction (37). Therefore, we treated the lysates
containing Z and p65 with DEAE-Sephacel to remove any
DNA present (1). Figure 3B demonstrates that DEAE-Sepha-
cel treatment totally eliminates a tracer probe (to which p65 is
known to bind) from all lysates used in Fig. 3A. In these
DNA-free lysates, 35S-labeled Z and p65 retain the ability to
interact with GST-p65 and GST-Z, respectively (Fig. 3A).
The dimerization domain of Z is required for the Z-p65
interaction. To ascertain further which domain of Z is needed
for binding directly to p65, each of a series of truncated Z
proteins was linked to GST (Fig. 2A), and each fusion protein
was tested for the ability to precipitate 35S-labeled p65. The Z
proteins lacking a transactivation domain retained the ability
to precipitate p65 (Fig. 2D, GST ZA1-79 and GST Z1l-133).
However, specific deletion of the dimerization domain was
shown to eliminate the Z-p65 interaction. These data suggest
that the coiled-coil domain of Z is required for the interaction
with p65.
To further establish that the dimerization domain of Z is
required for the interaction with p65 and to determine which
amino acid residues within the coiled-coil are critical, various
mutant forms of the Z protein were tested for the ability to
multimerize with p65 (Fig. 4). These mutant Z proteins all
contain two site-directed mutations within the dimerization
domain (mutants are numbered for the amino acids which
were mutated, and letters indicate which residues replaced the
wild-type amino acids). The abilities of the GST-Z and GST-
p65 fusions to complex with the various Z mutants were
compared. Mutants Z205R/206D and Z209R/216E as well as
wild-type Z protein all demonstrated the capacity to ho-
modimerize with GST-Z. These same Z proteins interacted
efficiently with GST-p65. The remaining Z mutants were found
to be incapable of efficient homodimerization (as was previ-
ously reported [20]) and also failed to interact with GST-p65.
Mapping the portion of p65 required for the interaction
with Z. To similarly determine which part of the p65 protein is
needed for contact with Z, we tested the ability of a series of
35S-labeled mutant and truncated p65 proteins to interact with
the GST-Z fusion protein (Fig. 5A). All of these in vitro-
translated p65 proteins were present in similar amounts (data
not shown). None of the p65 proteins reacted nonspecifically
to the GST protein linked to GSH-agarose beads (Fig. SB).
Wild-type p65 and a mutant p65 form, p65 ANLS, both were
efficiently precipitated by GST-Z. The p65 ANLS protein,
which contains a four-amino-acid substitution within a nuclear
localization signal and is incapable of interacting with the IKBQx
protein (6), still interacted efficiently with Z. Deletion of the
last 238 amino acids of p65, which contain the transactivation
domain, did not affect the Z-p65 interaction. However, dele-
tion of the region between amino acids 286 through 313
destroyed the ability of p65 to interact with Z. Although the
portion of p65 between amino acids 285 and 314 is needed for
the binding of p65 to both IKBa and Z, the precise amino acids
which are required are not identical, since the p65 ANLS
mutant can interact with Z but not IKBoQ.
We also tested whether the p65A protein (which lacks 10
amino acids within the Rel homology domain of p65 and was
incapable of fully inhibiting transactivation of the BHRF1
promoter by Z) might be incapable of efficient interaction with
GST-Z. As shown in Fig. 6 (lanes 5, 8, and 11), GST-Z
efficiently precipitated 35S-labeled, in vitro-translated Z and
p65 proteins. However, although equal amounts of p65 and
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FIG. 2. The direct physical interaction between Z and p65 requires the carboxy terminus of Z. (A) Map of the Flag Z protein containing all
245 amino acids of Z linked to an N-terminal Flag antibody epitope (F) with a kinase site for 3ZP labeling (8). The transactivation (TA),
DNA-binding (DNA), and coiled-coil dimerization (DIM) domains of Z are also shown. The Flag ZACOOH protein lacks the last 74 amino acids
of Flag Z. A map of GST Z which contains the GST protein from pGEX-3X (Pharmacia) linked to the wild-type full-length Z protein is shown
along with various truncated Z proteins which have also been linked to GST. The truncated Z proteins are named by the amino acid residues which
have been removed. (B) The GST protein or the GST-p65 fusion protein was linked to GSH-agarose beads, and these beads were incubated with
Flag Z protein which had been labeled with 32p to a high specific activity. Precipitated bead-protein complexes were washed five times and loaded
on an SDS-polyacrylamide gel. (C) To map the portion of Z necessary for the Z-p65 interaction, a truncated form of Z was also tested in GST
precipitation experiments performed as described for panel B. The first two lanes show 5,000 cpm of 32P-labeled Flag Z and Flag ZACOOH loaded
directly on the SDS-polyacrylamide gel. Flag Z was reacted with GSH-agarose beads coated with GST protein or with GST-p65 protein, as
indicated. On the same gel, Flag ZACOOH was reacted with GSH-agarose beads coated with GST protein, or with GST-p65 protein, as indicated.
(D) To determine which domains of the Z protein are necessary for the Z-p65 physical interaction, GST fusion proteins containing various
truncated forms of the Z protein were linked to GSH-agarose beads and incubated with in vitro-translated, 35S-labeled p65 protein. The
carboxy-terminal 112 amino acids (GST ZA1-133) were sufficient for the interaction with p65, yet the truncated Z protein lacking the coiled-coil
dimerization domain failed to precipitate p65. The GST-Z fusion proteins were present on the beads in similar amounts (data not shown). The
p65 protein retained by GST-Z appeared lighter than the previous experiments because of the use of 35S-labeled protein (versus 32P-labeled Z
protein in panels B and C).
p65A protein were used (Fig. 6, lanes 2 and 3), significantly
more p65 than p65A protein bound to Z (Fig. 6, lanes 8 and
11). This result provides further evidence that the Rel homol-
ogy domain of p65 is required for the interaction with Z.
Z and p65 can be coimmunoprecipitated in vitro and in vivo.
We used coimmunoprecipitation as a second method to con-
firm the physical interaction between Z and p65. In the first set
of experiments, the source of p65 protein was the GST-p65
fusion protein and the source of Z was 32P-labeled Flag Z (Fig.
2A). Rabbit anti-p65 serum, as expected, could specifically
precipitate 35S-labeled p65, whereas the preimmune rabbit
serum did not (Fig. 7, last two lanes). Preimmune serum did
not precipitate Z in the presence of GST-p65 or the negative
control GST protein alone. Anti-p65 serum could not precip-
itate Z in the absence of p65, but when GST-p65 was added
with 32P-labeled Z, the Z was coprecipitated.
We also performed coimmunoprecipitations to confirm that
an interaction between Z and p65 occurs in vivo, using HeLa
cells transfected exactly as those used for Fig. 1. Rabbit
anti-p65 serum added to extracts from HeLa cells which had
been transfected with expression vectors for Z and for p65
coprecipitated Z protein (Fig. 8A, lower panel, lane 4). Even in
the absence of transfected p65, the Z protein produced from
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FIG. 3. Z and p65 interact in a DNA-independent manner. (A)
35S-labeled Z and p65 proteins were reacted with the GST protein
(pGEX-3X) or the GST-Z and GST-p65 fusion proteins both before
(Pre-Cleared) and after treatment of all protein extracts with DEAE-
Sephacel. Load lanes contain 35S-labeled Z and p65 proteins directly
loaded onto the protein gel as markers. (B) All of the extracts used in
panel A were treated with DEAE-Sephacel to remove DNA present in
the bacterial extracts and reticulocyte lysates. A marker 32P-labeled
probe is shown for all extracts before (Pre-Cleared) and after (DEAE-
Sephacel) treatment, demonstrating complete removal of any DNA
present in the extracts.
its interaction with endogenous p65 protein (Fig. 8A, lower
panel, lane 2). Z protein was not nonspecifically precipitated
by normal rabbit serum. These data imply that the direct
physical interaction between Z and p65 may mediate the
functional inhibition of Z transactivation by p65.
Even stronger evidence that an interaction between Z and
p65 occurs in vivo was demonstrated by using the endogenous,
virally produced Z protein from the EBV-positive cell line
P3HR1. These cells were treated with sodium butyrate and
TPA to induce the expression of Z protein. Anti-p65 serum
coimmunoprecipitated endogenous p65 and Z protein from
induced cells but not from latently infected, uninduced P3HR1
cells which do not express Z protein (Fig. 8B). Thus, the Z and
p65 proteins appear to associate through a direct physical
interaction both in vitro and in vivo.
DISCUSSION
In this report, we have demonstrated that the EBV Z
protein, which triggers the switch from latent to lytic infection,
can interact directly with the p65 component of NF-KB. This
interaction is mediated through the coiled-coil dimerization
domain of Z and the Rel homology domain of p65. We
demonstrate that p65 inhibits the ability of Z to transactivate
early EBV promoters. Therefore, B-cell-specific nuclear ex-
pression of NF-KB or other Rel proteins may be one mecha-
nism of promoting EBV latency in B cells.
Heteromultimerization not only within families of transac-
tivators but also between whole classes of transactivators
Direct Loa
C
FIG. 4. The same amino acids of Z which are important for
homodimer formation are required for the Z-p65 interaction. (A) GST
precipitation experiments were performed similarly to those in Fig. 2.
Either reticulocyte lysates containing no Z RNA (- Retic. Lysate) or
in vitro-translated, 35S-labeled Z wild-type (Z WT) or Z mutant
proteins were reacted with GSH-agarose beads coated with GST
protein or with GST-Z protein, as indicated. Mutant forms of the Z
protein are named for the locations of the amino acid residues of Z
that have been mutated and indicate the amino acids which now are
present in place of the wild-type amino acids. (B) The 35S-labeled Z
proteins were incubated with GSH-agarose beads coated with GST
protein or with GST-p65 protein, as indicated. (C) The various forms
of 35S-labeled Z proteins were loaded directly on an SDS-polyacryl-
amide gel to demonstrate that similar counts per minute of protein
were used in all of the conditions in panels A and B.
increases the complexity in regulation of gene expression.
Recently, members of the bZIP family have been shown to
directly interact with a number of diverse proteins, including
helix-loop-helix-containing transcription factors (7, 8), steroid
receptors (61), and the TATA-binding protein (41). Of partic-
ular relevance to the Z-p65 interaction described here are the
recent reports showing that another bZIP protein (NF-IL6)
can interact directly with both NF-KB p50 (38) and p65 (67).
Interestingly, as is the case with the Z-p65 interaction, the
p65-NF-IL6 interaction requires the Rel domain of p65 and
the leucine zipper of NF-1L6 (67).
The leucine zipper domain of Z and the Rel domain of p65
are responsible for homodimerization of the respective pro-
teins (10, 20, 35, 52, 58) but also appear to be important
mediators of interactions with other proteins. We found that
the Z mutants which disrupt homodimerization by interfering
with the hydrophobic face of the Z coiled-coil domain (20) are
also unable to interact with p65 (Fig. 4). It is possible that the
hydrophobic face of the zipper which normally contacts a
second Z monomer contacts p65 instead, thereby excluding Z
from forming a functional binding protein or perhaps changing
the specificity ofDNA binding by Z. Alternatively, it is possible
that while the Z homodimerization domain is necessary for the
Z-p65 interaction, the interaction between Z and p65 is
p65-_ _
MOL. CELL. BIOL.
GST i - GST-p65 I









Direct L,oad Z p 65 p65A
s ,, s



















FIG. 5. Mapping the region of the p65 protein necessary for the
interaction with Z. (A) Maps of wild-type (WT), mutant, and dele-
tional forms of the p65 protein (translated in vitro and 35S labeled). To
generate the p65 ANLS protein, a four-amino-acid mutation from
KRKR to DQNQ was introduced in the nuclear localization signal of
p65. Carboxy-terminal deletion proteins were named by using the
number corresponding to the terminal amino acid residue. (B) The
panel of p65 proteins was reacted with GSH-agarose beads coated with
GST protein or with GST-Z (wild-type) protein, as indicated. Each p65
protein was expressed in vitro at the same level, and the arrows show
where loaded aliquots of the indicated proteins ran on the gel.
mediated through another, yet unmapped portion of the Z
protein.
As is the case for the p65 interaction with NF-1L6, the Rel
portion of p65 was also found to be essential for interaction
with Z. The p65 protein has been noted to contain a putative
leucine zipper, the disruption of which interferes with the
function of the p65 activation domain (58). Although this motif
theoretically might dimerize with Z, the leucine zipper is
located in the carboxy-terminal portion of p65 which is dis-
pensable for binding to Z. Additionally, the p65A protein
(which lacks amino acids 222 to 231 of p65) contains an intact
leucine zipper, yet p65A interacts less efficiently with Z than
does full-length p65 protein.
Interactions of viral proteins with NF-KB are not without
precedent; however, the physical binding of Z to p65 is a novel
mechanism of viral interaction with NF-KB. Functional NF-KB
binding sites are found in the regulatory regions controlling the
expression of important proteins encoded by several viruses
(12, 46, 47, 55, 60). The Tax protein of human T-cell leukemia
virus type I can interact directly with the p105 precursor of
1 2 3 4 5 6 7 8 9 10 11 12
FIG. 6. The same portion of p65 which is important for multimer-
ization is required for efficient protein-protein interaction with Z. In
vitro-translated, 35S-labeled wild-type Z, wild-type p65, and p65A (the
last protein in Fig. 5A) were directly loaded in lanes 1 to 3 at 1/25 the
amount used in GST precipitation conditions shown in lanes 4 to 12.
GSH-agarose beads coated with the GST, GST-Z, or GST-p65 pro-
teins were reacted with 335S-labeled Z (lanes 4 to 6), p65 (lanes 7 to 9),
or p65A (lanes 10 to 12). The p65A protein, which multimerizes poorly
with native p65 (illustrated by the fold decrease from lane 9 to lane 12)
interacts even less with Z (note the fold decrease from lane 8 to lane
11).
NF-KB p50 (28). The human immunodeficiency virus type 1
protease processes the p105 precursor to a functional p50
product (54). Numerous viruses exhibit the capacity to trans-
activate promoters through NF-KB sites (reviewed in reference
2). Interestingly, the EBV LMP1 protein, which is expressed in
latently infected B cells, also activates both the human immu-
nodeficiency virus long terminal repeat (25) and the cellular
A20 zinc finger protein (36) through NF-KB sites. The induc-
tion of NF-KB activity by LMP1 could potentially strengthen
the latent state by inhibiting Z protein function.
In contrast to the positive effect that NF-KB has on viral
replication in the preceding examples, EBV appears to use
Preimmune serum + + _ +
Anti-p65 serum + +.
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FIG. 7. The Z protein can be coimmunoprecipitated with p65. In
vitro, bacterially expressed GST-p65 protein (or GST protein alone as
a negative control) was reacted with 39P-labeled Flag Z protein (Fig.
2A) and then incubated with rabbit preimmune serum or rabbit
anti-p65 serum, as shown in the conditions specified above lanes 1 to
4. The 329P-labeled Z protein was added in equal amounts to all of the
reactions shown in lanes I to 4; however, Z was precipitated only in the
presence of p65 protein and anti-p65 antibody (lane 4). Equal counts
of in vitro-translated, 35S-labeled p65 protein were added to lanes 5
and 6 to demonstrate that the anti-p65, but not the preimmune serum,
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FIG. 8. The Z and p65 proteins form a complex in vivo. (A) HeLa
cells were transfected with 3 ,ug each of pHD1013 plus pCMV-4T (lane
1), CMV-Z plus pCMV-4T (lane 2), pCMV-p65 plus pHD1O13 (lane
3), or pCMV-p65 plus CMV-Z (lane 4). Whole cell lysates of the
transfected HeLa cells were divided and either loaded directly onto an
SDS-polyacrylamide gel and then subjected to Western transfer (upper
two panels) or first immunoprecipitated with normal rabbit serum
(third panel) or rabbit anti-p65 serum (fourth panel) and then
subjected to immunoblotting. Anti-p65 rabbit serum was used to probe
the first immunoblot, and an anti-Z monoclonal antibody was used to
probe the last three blots. The anti-p65 serum, but not the normal
rabbit serum, coimmunoprecipitated p65 and Z (compare lane 4 for
the bottom two panels). The low level of endogenous, untransfected
p65 present in the HeLa cells can also complex with Z (see the faint Z
band which has been coimmunoprecipitated in lane 2, lower panel).
(B) Whole cell lysates of P3HR1 cells (both uninduced or induced with
sodium butyrate and TPA) were divided and either loaded directly
onto an SDS-polyacrylamide gel and then subjected to Western
transfer (two right panels) or first immunoprecipitated (IP) with
normal rabbit serum or rabbit anti-p65 serum (lower left panel) and
then subjected to immunoblotting. Anti-p65 rabbit serum was used to
probe the right upper immunoblot, and an anti-Z monoclonal antibody
was used to probe the lower two blots. The level of p65 protein was
unchanged with induction (upper right panel). As expected, the level
of Z protein increased dramatically following induction (lower right
panel). Anti-p65 serum (not normal rabbit serum) coimmunoprecipi-
tated Z from the induced, but not from the uninduced, P3HR1 cell
extracts.
expression occurs (44). However, even a small amount of
"leaky" transcription in B cells might be expected to irrevers-
ibly launch the lytic viral cascade, since Z activates its own
expression (19, 71) as well as the expression of early EBV
promoters (9, 11, 13, 14, 16, 30, 31, 42, 43, 64, 71). The
presence of NF-KB in the nuclei of B cells could serve to
prevent such leaky expression of Z from initiating full viral
replication. On the other hand, elevated expression of IKB
could potentially lead to disruption of latency in B cells.
Interestingly, the phorbol ester TPA can serve both as an
inducer of NF-KB activity within the nucleus of some cells (62)
and as an inducer of Z expression (and EBV replication) in
EBV-infected B cells (77). While these observations would
appear to contradict our model of NF-KB inhibition of Z
function, the effect of TPA on NF-KB activity is transient,
reaching a maximum in several hours and then returning to
baseline by 8 to 24 h (49, 68). On the other hand, induction of
EBV productive infection by TPA is very slow, with an onset
following 2 to 3 days of exposure and reaching a maximum in
5 to 8 days (77). Hence, EBV is induced by TPA after NF-KB
activity has fallen to preinduced levels. It is therefore likely
that the disruption of EBV latency by TPA is mediated
through a different mechanistic pathway than that which
mediates TPA induction of NF-KB activity.
The cellular regulation of EBV latency is likely to be very
complex and involve multiple mechanisms. In addition to p65,
several other cellular proteins have been recently shown to
negatively regulate Z transactivation function through direct
protein-protein interactions. The cellular tumor suppressor
protein p53 inhibits Z-induced transactivation of both the
BMRF1 and BHRF1 promoters (76). This inhibition, which
involves a direct physical interaction between Z and p53,
requires the coiled-coil dimerization domain of Z and the
carboxy-terminal portion of p53 (76). In a similar manner, the
retinoic acid receptors, RARa and RXRot, repress the ability
of Z to transactivate the BMRF1 promoter and can physically
associate with the Z protein (65). In addition to negative
control of Z transactivation function, control of BZLF1 tran-
scription in different cell types must play a role in determining
whether EBV remains latent versus productive. In this regard,
we have recently shown that the BRLF1 promoter (one of two
EBV promoters driving Z expression) is constitutively active in
epithelial cells but inactive in B cells (75).
Although a number of cellular factors have been shown to
inhibit Z transactivation function, in certain circumstances
disruption of viral latency can occur, and therefore mecha-
nisms whereby these negative regulators of Z function can be
circumvented must also exist. Clearly, if Z transcription is
induced to a sufficient level, then Z can further activate its own
transcription and thereby produce enough protein to overcome
the effect of negative cellular regulators. Z transactivator
function in certain lymphocytic cell lines is increased by the
EBV BRLF1 immediate-early gene product (29) or the c-myb
oncogene product (32). In addition, the interactions between Z
and cellular proteins may well be influenced by Z phosphory-
lation, since there is recent evidence that Z is phosphorylated
in vivo and that dephosphorylation of Z is associated with the
disruption of viral latency (17). In any event, it is now clear that
the regulation of EBV latency is cell type specific and involves
interactions with numerous viral and cellular proteins.
NF-KB as an inhibitor of productive infection. Infection of
humans by EBV primarily involves epithelial cells and B cells
(33). In epithelial cells, the virus replicates efficiently, produc-
ing virions which are shed into the saliva (66). In B cells, EBV
exists primarily in a latent state in which little if any Z gene
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